Eradication of established tumors by CD8+ T cell adoptive immunotherapy. NLM AIDSLINE Important note: Information in this article was accurate in 2000. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Eradication of established tumors by CD8+ T cell adoptive immunotherapy.

Immunity. 2000 Aug;13(2):265-76. Unique Identifier : AIDSLINE MED/20434848
Hanson HL; Donermeyer DL; Ikeda H; White JM; Shankaran V; Old LJ; Shiku H; Schreiber RD; Allen PM; Department of Pathology and Center for Immunology, Washington; University School of Medicine, St. Louis, Missouri 63110, USA.

Abstract: We generated the DUC18 T cell receptor transgenic mouse expressing an H-2Kd -restricted transgenic T cell receptor specific for the syngeneic CMS5 fibrosarcoma rejection antigen mutated ERK2(136-144). DUC18 mice were capable of specifically eliminating lethal CMS5 tumor challenges, and transfer of DUC18 splenocytes to naive nontransgenic recipients conferred protection from subsequent and established CMS5 tumor burdens. Eradication of established tumor burdens by adoptive transfer of DUC18 splenocytes was dose and time dependent. Transferred tumor-specific T cells remained functional in vivo and capable of rejecting small tumors even in the presence of large, established tumor burdens. These findings highlight the kinetic battle between tumor growth and the production of a tumor-specific response and have critical implications for effective adoptive immunotherapy.

Keywords: JOURNAL ARTICLE Animal Antigens, Neoplasm/GENETICS/IMMUNOLOGY *Cytotoxicity, Immunologic CD8-Positive T-Lymphocytes/*IMMUNOLOGY/TRANSPLANTATION Fibrosarcoma/*IMMUNOLOGY/THERAPY *Immunotherapy, Adoptive Mice Mice, Transgenic Mutation Receptors, Antigen, T-Cell/GENETICS/*IMMUNOLOGY Support, Non-U.S. Gov't Support, U.S. Gov't, P.H.S.

KWDjournalarticleanimalantigens,neoplasm/genetics/immunologyKWDcytotoxicity,immunologiccd8-positivet-lymphocytes/KWDimmunology/transplantationfibrosarcoma/KWDimmunology/therapyKWDimmunotherapy,adoptivemicemice,transgenicmutationreceptors,antigen,t-cell/genetics/KWDimmunologysupport,non-uKWDsKWDgov'tsupport,uKWDsKWDgov't,pKWDhKWDs
001230
A00C0922

Copyright © 2000 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2000. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2000. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .